Abstract
The world population is aging and 60% of all cancer diagnoses and 70% of all cancer mortality occur in patients greater than 65years of age. The elderly have multiple medical and non-medical comorbidities that accompany changes in pharmacokinetics and pharmacodynamics and poly-pharmacy that all impact their treatment. The elderly derive benefit from cancer treatment but are often denied chemotherapy or are undertreated based on age. Treatment decision should be based on physiologic rather than chronological age and there is a need for inclusion of more elderly patients in cancer clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
